Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline - GBI Research Reports

Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline

Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline - GBI Research Reports
Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline
Published Sep 17, 2011
114 pages — Published Sep 17, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest research, Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline, provides in-depth analysis of unmet needs, drivers and barriers that impact the global coagulation disorders market. The report analyzes the markets for coagulation disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Market size, annual cost of therapy and treatment usage patterns are forecast until 2016 for the key geographies, as well as the leading therapeutic segments which includes hemophilia A, hemophilia B and von Willebrand Disease. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global coagulation disorders market.

Scope

The scope of this report includes -
- Annualized market data for the coagulation disorders market from 2002 to 2010, forecast forward to 2017.
- Analysis of the leading therapeutic segments, including hemophilia A, hemophilia B, and von Willebrands disease (vWD).
- Analysis of the coagulation disorders market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the coagulation disorders market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Baxter International Inc, Bayer AG, Novo Nordisk A/S, Pfizer Inc and CSL Behring LLC.
- Key M&A activities and licensing agreements that have taken place between 2004 and 2010 in the global coagulation disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with higher efficiency and better safety.
- Develop strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

  
Source:
Document ID
GBIHC074MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents45
  List of Tables61
  List of Figures72
Introduction91
  GBI Research Report Guidance91
Coagulation Disorders Therapeutics Market: Market Overview1012
  Introduction101
  Revenue Forecasts for the Global Coagulation Disorders Market111
    Revenue111
    Annual Cost of Therapy121
    Treatment Usage Pattern132
      Diseased Population151
      Treatment Seeking Population161
      Diagnosed Population171
      Prescription Population181
  Coagulation Disorders Market Drivers191
    Steady Increase in the Prevalence Population, Particularly in the Top Five Countries in Europe191
    Rapid Uptake of Recombinant Products due to Better Efficacy, Safety and Convenient Dosing191
    Increase in the Prescription Population due to Patent Expiries of Expensive Biologic Drugs, Making Them More Affordable201
  Coagulation Disorders Market Restraints211
    Low Diagnosed Population as Mild and Moderate Forms of Coagulation Disorders Go Undiagnosed211
    Patent Expiries of Major Blockbusters Including Kogenate FS, BeneFIX, NovoSeven, and ReFacto Pose a Threat to Leading Players in the Market211
    Sluggish Growth in the Annual Cost of Therapy for Coagulation Disorders is Expected to Drive Down the Growth Rate211
Global Coagulation Disorders Market: Geographical Landscape2216
  Geographical Break-up222
  The US241
    Revenue241
    Annual Cost of Therapy251
    Treatment Usage Patterns261
      Diseased Population271
      Treatment Seeking Population271
      Diagnosed Population281
      Prescription Population281
  Top Five Countries in Europe291
    Revenue291
    Annual Cost of Therapy301
    Treatment Usage Pattern311
      Diseased Population321
      Treatment Seeking Population321
      Diagnosed Population321
      Prescription Population331
  Japan341
    Revenue341
    Annual Cost of Therapy351
    Treatment Usage Patterns361
      Diseased Population371
      Treatment Seeking Population371
      Diagnosed Population371
      Prescription Population371
Coagulation Disorders Therapeutics Market: Therapeutic Landscape3835
  Hemophilia A Market381
    Introduction383
    Revenue412
      Geographic Segmentation431
      Branded vs. Generics441
    Annual Cost of Treatment451
    Treatment Flow Algorithm461
    Treatment Usage Pattern471
      Diseased Population481
      Treatment Seeking Population481
      Diagnosed Population491
      Prescription Population491
  Hemophilia B Market501
    Introduction503
    Revenue531
      Geographic Segmentation541
      Branded vs. Generics551
    Annual Cost of Treatment561
    Treatment Flow Algorithm571
    Treatment Usage Pattern581
      Diseased Population591
      Treatment Seeking Population591
      Diagnosed Population601
      Prescription Population601
  von Willebrand Disease (vWD) Market601
    Introduction605
    Revenue651
      Geographic Segmentation661
      Branded vs. Generics671
    Annual Cost of Treatment681
    Treatment Flow Algorithm691
    Treatment Usage Pattern701
      Diseased Population711
      Treatment Seeking Population711
      Diagnosed Population711
      Prescription Population721
Coagulation Disorders Therapeutics Market to 2017: Pipeline Analysis7314
  Introduction731
    Research and Development Pipeline Hemophilia743
    Research and Development Pipeline von Willebrand Disease (vWD)771
  Profiles of Key Late-Stage Drugs in the Coagulation Disorders Market781
    NecLip-pdFVIII781
      Introduction781
      Mechanism of Action781
      Clinical Trial Management781
    Long Acting rFactor VIII781
      Introduction781
      Mechanism of Action781
      Clinical Trial Management791
    OBI-1791
      Introduction791
      Mechanism of Action791
      Clinical Trial Management791
    Recombinant Factor IX Fc Fusion Protein (rFIXFc)801
      Introduction801
      Mechanism of Action801
      Clinical Trial Management801
    NN7008811
      Introduction811
      Mechanism of Action811
      Clinical Trial Management811
    Human-cl rhFVIII811
      Introduction811
      Mechanism of Action821
      Clinical Trial Management821
    BAX 326821
      Introduction821
      Mechanism of Action821
      Clinical Trial Management831
    IB1001831
      Introduction831
      Mechanism of Action831
      Clinical Trial Management831
    NNC-0156-0000-0009841
      Introduction841
      Mechanism of Action841
      Clinical Trial Management841
    Biostate841
      Introduction841
      Mechanism of Action841
      Clinical Trial Management851
    Long Acting rFactor IX851
      Introduction851
      Mechanism of Action851
      Clinical Trial Management861
Global Coagulation Disorders Market: Competitive Landscape8717
  Competitive Profiling871
    Baxter International Inc.871
      Product Portfolio872
      SWOT891
    Novo Nordisk A/S891
      Product Portfolio901
      SWOT911
    Pfizer Inc.911
      Product Portfolio921
      SWOT921
    CSL Behring LLC931
      Product Portfolio931
      SWOT941
    Bayer AG941
      Product Portfolio941
      SWOT951
    LFB951
      Product Portfolio951
      SWOT961
    Grifols961
      Product Portfolio963
      SWOT991
    Biotest991
      Product Portfolio991
      SWOT1001
    Bio Product Laboratory1001
      Product Portfolio1001
      SWOT1011
    Octapharma1011
      Product Portfolio1012
      SWOT1031
Global Coagulation Disorders Market: Strategic Consolidations1044
  Overview1041
    Baxter International Acquire Hemophilia-Related Assets from Archemix in November 20101051
    Paul Capital Healthcare Acquires Rights to Xyntha from Dyax in April 20101051
    Baxter Healthcare Acquires Rights to AV513 from Avigen in December 20081051
    Bayer HealthCare Enters Into Licensing Agreement with Zilip-Pharma1051
    Wyeth Enters Into Licensing Agreement with Nautilus Biotech1061
    Deals by Geography1061
    Deals by Value ($)1071
Global Coagulation Disorders Market: Appendix1087
  Market Definitions1081
  Abbreviations1081
  Research Methodology1092
    Coverage1091
    Secondary Research1091
    Primary Research1101
  Therapeutic Landscape1103
    Epidemiology-based Forecasting1111
    Market Size by Geography1121
  Geographical Landscape1131
  Pipeline Analysis1131
  Competitive Landscape1131
    Expert Panel Validation1131
  Contact Us1131
  Disclaimer1131
  Sources1141

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline" Sep 17, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Coagulation-Disorders-Market-to-2017-Hemophilia-A-the-Largest-Segment-to-Witness-a-Decline-in-Growth-Rate-due-to-Patent-Expiries-and-Weak-Pipeline-2115-256>
  
APA:
GBI Research Reports. (2011). Coagulation Disorders Market to 2017 - Hemophilia A, the Largest Segment, to Witness a Decline in Growth Rate due to Patent Expiries and Weak Pipeline Sep 17, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Coagulation-Disorders-Market-to-2017-Hemophilia-A-the-Largest-Segment-to-Witness-a-Decline-in-Growth-Rate-due-to-Patent-Expiries-and-Weak-Pipeline-2115-256>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.